Brentuximab Vedotin Approved for Two Rare Lymphomas

| December 19, 2017 | 0 Comments
Brentuximab Vedotin Approved for Two Rare Lymphomas

FDA has approved brentuximab vedotin (Adcetris®) for the treatment of adults who have been treated previously for either primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides, two rare lymphomas that start as rashes on the skin.
See Original Article

NCI: Taking Risks to Advance Science

Norman Sharpless, M.D., offers his thoughts on his experience thus far as NCI director and areas, like big data, where NCI can play an important role in advancing science.
See Original Article

Prior Cancers Common in Patients Newly Diagnosed with Cancer

A new study shows that many patients diagnosed with a new cancer have had one or more cancers in the past, which has potential implications for long-term surveillance and clinical trial enrollment.
See Original Article

Category: Recent News

About the Author ()

Leave a Reply